VINCENT BRYAN: Open Payments
NPI 1134129356 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,498 in 75 payments from 19 companies in 2025. Trend: 2023 $1,988 · 2024 $1,879 · 2025 $1,498
Food & beverage: $1,463Education: $35
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $256 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $212 |
| Novo Nordisk Inc | 9 | $193 |
| PFIZER INC. | 9 | $169 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $146 |
| AstraZeneca Pharmaceuticals LP | 5 | $79 |
| Dexcom, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Abbott Laboratories | 3 | $52 |
Products named: Kerendia, CAPLYTA, NURTEC ODT, VRAYLAR, Ozempic, UBRELVY, Dexcom G6 Transmitter, Leqembi.
Industry payments across OK — which companies pay providers there.
